Forte Biosciences (FBRX) CEO Receives 1,250 RSUs; Holds 82,092 Shares

Paul A. Wagner, CEO, Secretary and Chair of Forte Biosciences, Inc. (FBRX), reported an award of 1,250 restricted stock units (RSUs) on 10/01/2025.

Rhea-AI Filing Summary

Paul A. Wagner, CEO, Secretary and Chair of Forte Biosciences, Inc. (FBRX), reported an award of 1,250 restricted stock units (RSUs) on 10/01/2025. Each RSU converts into one share of common stock at $0. The RSUs vest in 16 quarterly installments (one-sixteenth each) beginning on or immediately after February 1, 2023, subject to continued service under the 2021 Equity Incentive Plan. The report also shows a separate sale of 98 shares on 10/01/2025 at $14.52, leaving total beneficial ownership of 82,092 shares after the transactions.

Positive

• 1,250 RSUs awarded to a named insider, indicating ongoing executive alignment with shareholder interests
• RSUs vest over 16 quarterly installments, tying compensation to continued service under the 2021 Equity Incentive Plan
• Reporting person retains 82,092 shares after transactions

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Insider received 1,250 RSUs with time-based vesting; holds 82,092 shares after a small sale.

The reporting shows a time-vested equity award rather than an immediate stock grant or cash purchase, indicating compensation tied to continued service under the 2021 Equity Incentive Plan. The RSUs convert at $0, meaning the award is a compensation vehicle that will issue shares upon vesting.

The filing also discloses a minor disposition of 98 shares at $14.52 on 10/01/2025, leaving the reporting person with 82,092 shares. The roles listed (CEO, Secretary and Chair) identify the reporter as a principal insider required to disclose Section 16 transactions.

Insider Trade Summary

1,250 shares exercised/converted

Exercise 3 txns

Insider Wagner Paul A.

Role SEE REMARKS

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,250	$0.00	$0.00
Exercise	Common Stock	1,250	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	98	$14.52	$1K

Holdings After Transaction: Restricted Stock Units — 6,250 contracts (Direct); Common Stock — 82,092 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

FAQ

What did Paul A. Wagner report on Form 4 for FBRX?

He reported receiving 1,250 RSUs on 10/01/2025 and a sale of 98 shares at $14.52 the same day, leaving 82,092 shares beneficially owned.

How do the RSUs awarded to the FBRX insider vest?

The RSUs vest one-sixteenth (1/16th) on each quarterly vesting date (January 1, April 1, July 1, October 1) subject to continued service.

What conversion value was assigned to the RSUs in the Form 4?

Each RSU represents a contingent right to one share of common stock and is reported with a conversion price of $0.

How many shares does the reporting person own after the reported transactions?

The Form 4 shows 82,092 shares beneficially owned following the reported transactions.

What insider roles does Paul A. Wagner hold at Forte Biosciences?

The filing lists him as CEO, Secretary and Chair of the Board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Wagner Paul A.

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TX 75247

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		1,250	A	$0(1)	82,190	D
Common Stock	10/01/2025		F		98	D	$14.52	82,092	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	10/01/2025		M			1,250	(2)	(2)	Common Stock	1,250	$0	6,250	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Remarks:

CEO, Secretary and Chair of the Board

	/s/ Paul A. Wagner, Ph.D.	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.